Comparison
Dulaglutide vs. Efinopegdutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
923950-08-7
2055640-93-0
Molecular weight
59670 g/mol
no data
Half-life
110 h
115 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcmodifiziertes, von Oxyntomodulin abgeleitetes Peptid, konjugiert an ein humanes IgG4-Fragment (Verlängerung der Plasma-Halbwertszeit)Mechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Efinopegdutide
Efinopegdutide is an oxyntomodulin-derived peptide acting as a dual agonist at the GLP-1 and glucagon receptors with a relative potency of approximately 2:1 (GLP-1 to glucagon). The GLP-1 component mediates glucose-dependent insulin secretion and modulation of satiety; the glucagon component increases energy expenditure and hepatic fat oxidation, which is proposed to contribute to the observed reduction in liver fat. Conjugation to an IgG4 fragment prolongs the half-life and enables weekly administration.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
3
of which in humans
5
3
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Dulaglutide and Efinopegdutide?
- Dulaglutide is classified as "Metabolic", while Efinopegdutide is classified as "Metabolic". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Efinopegdutide: Efinopegdutide (MK-6024, formerly JNJ-64565111 / HM12525A) is a once-weekly dual agonist at the GLP-1 and glucagon receptors, developed by Hanmi and Merck. It has been studied for obesity and notably for metabolic liver disease (MASH/NAFLD); a phase-2 trial showed greater liver-fat reduction than semaglutide. Investigational, not approved. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Efinopegdutide?
- The highest available evidence level is "Human RCT" for Dulaglutide and "Human RCT" for Efinopegdutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Efinopegdutide in Germany and the United States?
- Germany: Dulaglutide — Prescription, Efinopegdutide — Unapproved. United States: Dulaglutide — Prescription, Efinopegdutide — Unapproved. These are factual summaries with source and review date on the individual pages.